Why It Matters

Campaign for Sustainable Drug Pricing terminated its lobbying relationship with Whitmer & Worrall LLC on June 4, according to a lobbying disclosure filed July 21.

The relationship represented a significant client engagement for the firm. Campaign for Sustainable Drug Pricing paid Whitmer & Worrall LLC $50,000 during the second quarter, the final reporting period before the termination. Over the course of the engagement, which spanned from the fourth quarter of 2023 through the second quarter of this year, the organization disclosed lobbying activity on multiple pieces of federal legislation, reflecting a sustained focus on prescription drug pricing and generic drug policy.

The termination comes after several bills the organization previously lobbied on failed to advance during the 118th Congress. H.R. 5958, the Drug-price Transparency for Consumers Act of 2023, died in committee after appearing in the organization's lobbying disclosures from late 2023 through mid-2024. H.R. 3839, the Generic Drug Application Transparency Act, and S. 775, the Increasing Transparency in Generic Drug Applications Act, also died in committee. Likewise, S. 1214, the RARE Act, and S. 2220, the PREVAIL Act, did not advance before the end of the Congress.

The new Congress brought a different legislative focus. Campaign for Sustainable Drug Pricing cited S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act, in its first-quarter lobbying disclosure. Introduced on March 24, 2025, the bipartisan bill was later reported by the Senate Judiciary Committee. S. 1097, the Interagency Patent Coordination and Improvement Act, introduced the same day, also appeared in the organization's second-quarter lobbying disclosure. Both measures are bipartisan.

The timing of the termination also coincided with executive branch activity on prescription drug pricing. President Trump signed an executive order on May 12, 2025, titled "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients," and the administration later announced additional actions related to most-favored-nation pricing. The lobbying disclosure does not indicate whether those executive actions influenced the organization's decision to end its contract with Whitmer & Worrall.

Broader Context

Prescription drug pricing has remained a recurring focus of congressional activity across multiple Congresses. Campaign for Sustainable Drug Pricing's engagement with Whitmer & Worrall spanned a period during which numerous legislative proposals were introduced, while others expired without receiving final action.

The organization's lobbying priorities shifted between the 118th and 119th Congresses. Earlier disclosures focused primarily on legislation addressing transparency requirements and patent-related issues affecting generic drugs. Later filings emphasized S. 1096 and S. 1097, reflecting a change in legislative priorities as Congress considered new bipartisan proposals related to generic drug competition.

At the same time, executive branch actions on prescription drug pricing created an additional avenue for federal policy changes, potentially reducing the emphasis on legislative advocacy. The available lobbying disclosures, however, do not explain why the organization ended its relationship with Whitmer & Worrall.

The Bottom Line

The lobbying disclosure contains no indication that Campaign for Sustainable Drug Pricing retained another lobbying firm after ending its relationship with Whitmer & Worrall LLC. The filing shows the organization concluded the engagement as Congress shifted to new prescription drug legislation and the Trump administration continued pursuing executive actions on drug pricing. Whether the organization changed its broader advocacy strategy cannot be determined from the public disclosure records alone.

Access the Legis1 platform for comprehensive political news, data, and insights.

Spot something wrong? Report an issue with this article